A Phase 3 interventional study of TAK-438 and TAK-438 in Non-erosive Gastroesophageal Reflux Disease, sponsored by Takeda. Completed at 52 sites in Japan. Open to participants aged 20 Years and older. Per ClinicalTrials.gov, last updated 2013-07-03.
Sponsored by Takeda · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 16 studies testing vonoprazan in Gastroesophageal Reflux — 5 open to participants now, 5 under way, 1 of them phase 3. vonoprazan · Gastroesophageal Reflux.
Among the 16 studies testing vonoprazan in Gastroesophageal Reflux, this one has the largest enrollment, is the only one that started in 2011, is one of 3 in phase 3, and was the 1st registered.
1,215 studies on the registry are indexed under Gastroesophageal Reflux; 203 are open to participants now.
Browse Gastroesophageal Reflux studies →5 of the 16 studies testing vonoprazan in Gastroesophageal Reflux are open now, in 4 countries. Recruiting first, the newest first:
Phathom Pharmaceuticals, Inc. · Sites in United States
Ages 18+
Asian Institute of Gastroenterology, India · Sites in India
Ages 18–75
Asian Institute of Gastroenterology, India · Sites in India
Ages 18–75
Tanta University · Sites in Egypt
Ages 17–60
Fu Jen Catholic University Hospital · Sites in Taiwan
Ages 20–75
By country, each count listing its studies:
vonoprazan: first FDA approval 2022 (VOQUEZNA TRIPLE PAK). What it is approved for, and how studies give it, is on its page →
Of the 133 Gastroesophageal Reflux studies recruiting now, 57 (43%) set no upper age limit and 53 (40%) stop at 75 or younger; 22 take children under 18; 20 take healthy volunteers.
This study: 20 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
16 studies; the count open now beside each. This study's row is marked.
First in 2008; this study’s year is marked. 1 started in 2011.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 827 is above the median of 68 across 799 interventional studies indexed under Gastroesophageal Reflux.
Median enrollment 118 across the 16 interventional studies. Of the 11 that completed or were terminated, 4 (36%) have results posted.
This tab as a report to print or save as PDF → With an account.
7 of 16 have an industry lead sponsor. The 10 most frequent:
Takeda is the lead sponsor of 1,026 studies on the registry; 88 are open to participants now.
Of its 178 completed or terminated interventional studies of FDA-regulated products, 154 (87%) have results posted.
41 studies in Gastroesophageal Reflux by Takeda: none open now, none under way, none of them phase 3. Of 39 finished, 22 (56%) have results posted.
Among the 41 studies in Gastroesophageal Reflux by Takeda, this one is the 6th largest by enrollment of the 36 interventional ones that give a count, is one of 2 that started in 2011, is one of 16 in phase 3, and was the 28th registered.
Takeda’s Gastroesophageal Reflux studies by the year they started, since 2000.
2 of the studies testing vonoprazan in Gastroesophageal Reflux that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07752407Phase 3Phathom Pharmaceuticals, Inc.A Study to Evaluate the Efficacy and Safety of Vonoprazan 10 mg Compared to Placebo for Relief of Episodic Heartburn in Participants With Symptomatic Non-Erosive Gastroesophageal Reflux Disease Through 24 Weeks | 2027-10-20 |
| NCT06953986Asian Institute of Gastroenterology, IndiaA Randomized, Three-Arm Study Comparing Vonaprazan 10 mg, Vonaprazan 20 mg, and Esomeprazole 40 mg for the Healing of LA Grade B or Higher Reflux Esophagitis at 8 Weeks | 2026-11-20 |
Add all 2 to your calendar (.ics) → With an account.
Among the 16 studies testing vonoprazan in Gastroesophageal Reflux, from their registry updates:
Among Takeda’s 41 in Gastroesophageal Reflux:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to investigate the superiority of efficacy of TAK-438, once daily (QD), to placebo in patients with non-erosive gastroesophageal reflux disease.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Participants with severity* of moderate or higher for acid reflux symptoms (heartburn or regurgitation) in the 3 weeks before initiation of the pre-observation period (VISIT 1)
* Severity: No symptoms, very mild (symptoms present but often forgotten), mild (not so painful), moderate (rather painful), severe (painful) and very severe (painful enough to affect night time sleep or daily activities)
Exclusion Criteria:
Drug: TAK-438
Drug: TAK-438
Drug: Placebo
TAK-438 10 mg, tablets, orally, once daily for 4 weeks. Thereafter, TAK-438 placebo tablets, orally, once daily for 1 week.
TAK-438 20 mg, tablets, orally, once daily for 4 weeks. Thereafter, TAK-438 placebo tablets, orally, once daily for 1 week.
TAK-438 placebo-matching tablets, orally, once daily for 5 weeks.
Percentage of symptom-free days of heartburn symptoms
Heartburn symptoms will be collected by participant diaries.
Time frame: Week 4
Cumulative symptom improvement rate of heartburn symptoms
Heartburn symptoms will be collected by participant diaries.
Time frame: Week 4
Severity of heartburn symptoms
Heartburn symptoms will be collected by participant diaries.
Time frame: Week 4
Heartburn symptoms stratified by response (improvement or non-improvement) at Week 2
Heartburn symptoms will be collected by participant diaries. Percentage of symptom-free days, cumulative symptom improvement rate, and severity of heartburn symptoms are evaluation parameters.
Time frame: Week 4
Heartburn Symptoms Stratified by Baseline Endoscopic Findings (Grade N or M)
Heartburn symptoms collected by participant diaries. Percentage of symptom-free days, cumulative symptom improvement rate and severity of heartburn symptoms=evaluation parameters. Participants with Non-Erosive Gastroesophageal Reflux Disease divided into Grade N (endoscopically normal) and M (minimal change) by modified Los Angeles Classification System. Grade definitions: Grade N (endoscopically normal), M (minimal change), A (Mucosal break \<5 mm) B (Mucosal break ≥5 mm) C (Mucosal break continuous between 2 or more folds and \<75% of circumference) and D (Mucosal break ≥75% of circumference).
Time frame: Week 4
Heartburn symptoms stratified by combination of response at Week 2 and baseline endoscopic findings (improvement and grade N, improvement and grade M, non-improvement and grade N, non-improvement and grade M.)
Heartburn symptoms will be collected by participant diaries. Percentage of symptom-free days, cumulative symptom improvement rate, and severity of heartburn symptoms are evaluation parameters.
Time frame: Week 4
The record gives a start of Dec 2011, a primary completion of Feb 2013 and a completion of Feb 2013. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2013. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Vonoprazan